Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10016124HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10004445HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10026818HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10025174HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10026819HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10035476HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS10026820HBVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS30085899HIVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS30032215HIVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TVIS20008358HPVENSG00000273079.7protein_codingGRIN2BNoNo2904Q13224
TCGA Plot Options
Drug Information
GeneGRIN2B
DrugBank IDDB01956
Drug NameTaurine
Target IDBE0000417
UniProt IDQ13224
Regulation Typeinhibitor
PubMed IDs25833525
CitationsChan CY, Singh I, Magnuson H, Zohaib M, Bakshi KP, Le Francois B, Anazco-Ayala A, Lee EJ, Tom A, YeeMon K, Ragnauth A, Friedman E, Banerjee SP: Taurine Targets the GluN2b-Containing NMDA Receptor Subtype. Adv Exp Med Biol. 2015;803:531-44. doi: 10.1007/978-3-319-15126-7_43.
GroupsApproved; Nutraceutical
Direct ClassificationOrganosulfonic acids
SMILESNCCS(O)(=O)=O
PathwaysCongenital Bile Acid Synthesis Defect Type II; Familial Hypercholanemia (FHCA); Bile Acid Biosynthesis; Zellweger Syndrome; Congenital Bile Acid Synthesis Defect Type III; Taurine and Hypotaurine Metabolism; 27-Hydroxylase Deficiency; Cerebrotendinous Xanthomatosis (CTX)
PharmGKBPA451590
ChEMBLCHEMBL239243